ProCE Banner Activity

KEYLYNK-009: Phase II Trial of Maintenance Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy in Untreated Metastatic or Locally Recurrent Inoperable TNBC

Conference Coverage
Slideset

Following induction therapy with pembrolizumab plus chemotherapy, maintenance therapy with pembrolizumab plus olaparib did not improve PFS or OS vs continuing pembrolizumab plus chemotherapy in patients with untreated metastatic or locally recurrent inoperable TNBC.

Released: December 07, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.